8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 30, 2026·SEC
Ligand Pharmaceuticals Incorporated(LGND)Earnings, Financials & Key Ratios
LGND•NASDAQ
44.8× P/E·Price updated Jun 19, 2026
AboutLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.Show more
- Revenue$268M+60.4%
- EBITDA$81M+541.0%
- Net Income$124M+3186.6%
- EPS (Diluted)6.13+2886.4%
- Gross Margin97.54%+4.5%
- EBITDA Margin30.2%+299.6%
- Operating Margin17.61%+230.2%
- Net Margin46.42%+2024.3%
- ROE13.47%+2658.2%
LGND Key Insights
Ligand Pharmaceuticals Incorporated (LGND) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 18.2% free cash flow margin
- ✓Momentum leader: RS Rating 88 (top 12%)
- ✓Strong 5Y sales CAGR of 10.4%
- ✓Healthy 5Y average net margin of 18.1%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 11.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LGND posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LGND Price & Volume
Ligand Pharmaceuticals Incorporated (LGND) stock price & volume — 10-year historical chart
Loading chart...
LGND Growth Metrics
Ligand Pharmaceuticals Incorporated (LGND) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years14.06%
5 Years10.39%
3 Years10.96%
TTM51.24%
Profit CAGR
10 Years-7.01%
5 Years-
3 Years-
TTM215.79%
EPS CAGR
10 Years-6.59%
5 Years-
3 Years-
TTM203.51%
Return on Capital
10 Years12.2%
5 Years2.28%
3 Years0.95%
Last Year3.89%
LGND Recent Earnings
Ligand Pharmaceuticals Incorporated (LGND) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$1.63-11.4%
$1.84
Rev
$52M-12.5%
$59M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$2.02+38.4%
$1.46
Rev
$60M+7.3%
$56M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$3.09+56.9%
$1.97
Rev
$115M+107.7%
$56M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.60+3.9%
$1.54
Rev
$48M-9.9%
$53M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $1.63vs $1.84-11.4% | $52Mvs $59M-12.5% |
| Q1 2026 | Feb 26, 2026 | $2.02vs $1.46+38.4% | $60Mvs $56M+7.3% |
| Q4 2025 | Nov 6, 2025 | $3.09vs $1.97+56.9% | $115Mvs $56M+107.7% |
| Q3 2025 | Aug 7, 2025 | $1.60vs $1.54+3.9% | $48Mvs $53M-9.9% |
Based on last 12 quarters of dataView full earnings history →
LGND Peer Comparison
Ligand Pharmaceuticals Incorporated (LGND) competitors in Royalty and IP Monetization Vehicles — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 OMAB | 5.5B | 114.00 | 17.79 | 5.91% | 33.46% | 50.64% | 1.19 | |
 RPRX | 22.69B | 52.96 | 29.42 | 5.06% | 33.9% | 8.54% | 0.92 | |
 BCYC | 277.05M | 4.00 | -1.27 | 105.77% | -344.95% | -35.74% | 0.03 | |
 XOMA | 525.34M | 41.89 | 28.69 | 83.06% | 86.97% | 30.21% | 1.27 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 |
Compare LGND vs Peers
Ligand Pharmaceuticals Incorporated (LGND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LGND Income Statement
Ligand Pharmaceuticals Incorporated (LGND) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 141.1M | 251.45M | 120.28M | 163.56M | 241.54M | 196.25M | 131.31M | 167.13M | 268.09M | 274.48M |
Revenue Growth % | 29.48% | 78.21% | -52.17% | 35.98% | 47.68% | -18.75% | -33.09% | 27.28% | 60.4% | 51.24% |
Cost of Goods Sold | 5.37M | 6.34M | 11.35M | 30.42M | 62.18M | 52.83M | 35.05M | 11.07M | 6.59M | 3.81M |
COGS % of Revenue | 3.8% | 2.52% | 9.43% | 18.6% | 25.74% | 26.92% | 26.69% | 6.63% | 2.46% | - |
Gross Profit | 135.74M▲ 0% | 245.12M▲ 80.6% | 108.94M▼ 55.6% | 133.14M▲ 22.2% | 179.37M▲ 34.7% | 143.42M▼ 20.0% | 96.27M▼ 32.9% | 156.06M▲ 62.1% | 261.5M▲ 67.6% | 270.66M▲ 0% |
Gross Margin % | 96.2% | 97.48% | 90.57% | 81.4% | 74.26% | 73.08% | 73.31% | 93.37% | 97.54% | 98.61% |
Gross Profit Growth % | 31.27% | 80.58% | -55.56% | 22.22% | 34.72% | -20.04% | -32.88% | 62.11% | 67.56% | - |
Operating Expenses | 67.66M | 81.39M | -698.14M | 95.64M | 75.52M | 140.38M | 84.32M | 178.66M | 214.3M | 169.88M |
OpEx % of Revenue | 47.95% | 32.37% | -580.42% | 58.48% | 31.26% | 71.53% | 64.21% | 106.9% | 79.94% | - |
Selling, General & Admin | 28.65M | 37.73M | 41.88M | 60.01M | 46.79M | 70.06M | 52.79M | 78.65M | 92.45M | 94.48M |
SG&A % of Revenue | 20.31% | 15.01% | 34.82% | 36.69% | 19.37% | 35.7% | 40.2% | 47.06% | 34.48% | - |
Research & Development | 26.89M | 27.86M | 55.91M | 40.5M | 32.1M | 36.08M | 24.54M | 21.43M | 81.18M | 33.24M |
R&D % of Revenue | 19.05% | 11.08% | 46.48% | 24.76% | 13.29% | 18.39% | 18.69% | 12.82% | 30.28% | - |
Other Operating Expenses | 12.12M | 15.79M | -795.93M | -4.87M | -3.38M | 34.24M | 7M | 78.59M | 40.67M | 2M |
Operating Income | 68.08M▲ 0% | 163.73M▲ 140.5% | 807.08M▲ 392.9% | 37.5M▼ 95.4% | 103.85M▲ 176.9% | 3.04M▼ 97.1% | 11.94M▲ 293.2% | -22.61M▼ 289.3% | 47.2M▲ 308.8% | 100.78M▲ 0% |
Operating Margin % | 48.25% | 65.11% | 670.99% | 22.93% | 42.99% | 1.55% | 9.09% | -13.53% | 17.61% | 36.72% |
Operating Income Growth % | 55.12% | 140.51% | 392.94% | -95.35% | 176.94% | -97.08% | 293.22% | -289.3% | 308.79% | - |
EBITDA | 80.6M | 180.42M | 850.81M | 65.47M | 154.8M | 46.43M | 48.46M | 12.63M | 80.97M | 127.02M |
EBITDA Margin % | 57.12% | 71.75% | 707.34% | 40.03% | 64.09% | 23.66% | 36.91% | 7.56% | 30.2% | 46.28% |
EBITDA Growth % | 46.07% | 123.86% | 371.57% | -92.31% | 136.45% | -70.01% | 4.38% | -73.93% | 540.97% | 578.15% |
D&A (Non-Cash Add-back) | 12.52M | 16.69M | 43.73M | 27.97M | 50.95M | 43.39M | 36.52M | 35.24M | 33.77M | 26.24M |
EBIT | 68.63M | 221.61M | 832.38M | 28.71M | 91.82M | 37.81M | 64.32M | 5.55M | 158.96M | 227.66M |
Net Interest Income | -11.4M | -34.28M | -7.32M | -19.34M | -18.73M | 247K | 7.05M | 5.02M | 8.94M | 12.95M |
Interest Income | 0 | 14M | 28.43M | 8.08M | 886K | 2.05M | 7.71M | 8.05M | 8.94M | 14.1M |
Interest Expense | 11.4M | 48.28M | 35.74M | 27.41M | 19.62M | 1.8M | 656K | 3.04M | 0 | 1.15M |
Other Income/Expense | -10.85M | 9.6M | -10.44M | -36.21M | -31.65M | 32.97M | 51.72M | 25.12M | 111.76M | 84.1M |
Pretax Income | 57.23M▲ 0% | 173.33M▲ 202.9% | 796.64M▲ 359.6% | 1.29M▼ 99.8% | 72.2M▲ 5488.6% | 36.01M▼ 50.1% | 63.66M▲ 76.8% | 2.52M▼ 96.0% | 158.96M▲ 6212.9% | 184.88M▲ 0% |
Pretax Margin % | 40.56% | 68.93% | 662.31% | 0.79% | 29.89% | 18.35% | 48.48% | 1.51% | 59.29% | 67.36% |
Income Tax | 44.67M | 30.01M | 167.34M | -5.31M | -4.15M | 41.23M | 9.84M | 6.55M | 34.51M | 31.32M |
Effective Tax Rate % | 78.06% | 17.31% | 21.01% | -410.68% | -5.74% | 114.49% | 15.46% | 260.13% | 21.71% | 16.94% |
Net Income | 12.56M▲ 0% | 143.32M▲ 1041.5% | 629.3M▲ 339.1% | -2.98M▼ 100.5% | 57.14M▲ 2014.2% | -33.36M▼ 158.4% | 52.15M▲ 256.3% | -4.03M▼ 107.7% | 124.45M▲ 3186.6% | 153.56M▲ 0% |
Net Margin % | 8.9% | 57% | 523.19% | -1.82% | 23.66% | -17% | 39.72% | -2.41% | 46.42% | 55.95% |
Net Income Growth % | 867.48% | 1041.45% | 339.09% | -100.47% | 2014.17% | -158.39% | 256.33% | -107.73% | 3186.63% | 215.79% |
Net Income (Continuing) | 12.56M | 143.32M | 629.3M | 6.6M | 76.35M | -5.22M | 53.82M | -4.03M | 124.45M | 153.56M |
Discontinued Operations | 0 | 0 | 0 | -9.58M | -19.21M | -28.14M | -1.67M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.53▲ 0% | 5.96▲ 1024.5% | 31.85▲ 434.4% | -0.18▼ 100.6% | 3.34▲ 1955.6% | -1.98▼ 159.3% | 2.94▲ 248.5% | -0.22▼ 107.5% | 6.13▲ 2886.4% | 7.72▲ 0% |
EPS Growth % | 775.16% | 1024.53% | 434.4% | -100.57% | 1955.56% | -159.28% | 248.48% | -107.48% | 2886.36% | 203.51% |
EPS (Basic) | 0.60 | 5.96 | 33.13 | -0.18 | 3.46 | -1.98 | 3.02 | -0.22 | 6.44 | - |
Diluted Shares Outstanding | 23.48M | 24.07M | 19.76M | 16.18M | 17.25M | 16.87M | 17.76M | 18.29M | 20.29M | 19.88M |
Basic Shares Outstanding | 21.03M | 24.05M | 19M | 16.18M | 16.63M | 16.87M | 17.3M | 18.29M | 19.34M | 19.88M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LGND Balance Sheet
Ligand Pharmaceuticals Incorporated (LGND) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 237.02M | 870.54M | 1.12B | 500.56M | 464.75M | 263.6M | 237.43M | 331.56M | 832.27M | 865.41M |
Cash & Short-Term Investments | 201.66M | 764.57M | 1.07B | 411.19M | 341.11M | 211.87M | 170.31M | 256.17M | 733.52M | 779.4M |
Cash Only | 201.66M | 718.38M | 71.54M | 47.62M | 19.52M | 45.01M | 22.95M | 72.31M | 174.93M | 115.08M |
Short-Term Investments | 0 | 46.19M | 998.32M | 363.57M | 321.59M | 166.86M | 147.35M | 183.86M | 558.59M | 664.33M |
Accounts Receivable | 25.6M | 55.85M | 41.75M | 59.06M | 91.65M | 35.04M | 39.31M | 42.45M | 61.05M | 54.8M |
Days Sales Outstanding | 66.21 | 81.07 | 126.69 | 131.81 | 138.49 | 65.17 | 109.27 | 92.7 | 83.12 | 71.83 |
Inventory | 4.37M | 7.12M | 7.3M | 26.49M | 27.33M | 13.29M | 23.97M | 14.11M | 9.13M | 13.27M |
Days Inventory Outstanding | 297.46 | 410.33 | 234.69 | 317.82 | 160.42 | 91.85 | 249.61 | 465.2 | 505.65 | 1.13K |
Other Current Assets | 5.39M | 89.19M | 4.73M | 3.82M | 4.67M | 2.27M | 2.66M | 16.9M | 28.58M | 17.95M |
Total Non-Current Assets | 434M | 390.26M | 371.27M | 861.73M | 832.84M | 499.07M | 549.79M | 610.22M | 728.37M | 666.69M |
Property, Plant & Equipment | 4.21M | 5.37M | 17.62M | 37.17M | 32.6M | 27.49M | 25.06M | 24.81M | 10.79M | 0 |
Fixed Asset Turnover | 33.50x | 46.81x | 6.83x | 4.40x | 7.41x | 7.14x | 5.24x | 6.74x | 24.84x | 32.78x |
Goodwill | 314.54M | 306.44M | 95.23M | 189.66M | 105.67M | 105.67M | 103.37M | 105.25M | 101.54M | 101.54M |
Intangible Assets | 19.53M | 31.46M | 230.54M | 606.31M | 386.8M | 352.64M | 299.61M | 266.65M | 422.31M | 217.34M |
Long-Term Investments | 6.44M | 601.22M | 0 | 0 | 0 | 3M | 111.61M | 10.91M | 183.58M | 461.56M |
Other Non-Current Assets | 4.86M | -600.75M | 2.27M | 4.27M | 272.03M | 1.74M | 9.92M | 202.53M | 1.79M | 307.82M |
Total Assets | 671.02M▲ 0% | 1.26B▲ 87.9% | 1.49B▲ 18.6% | 1.36B▼ 8.9% | 1.3B▼ 4.7% | 762.67M▼ 41.2% | 787.22M▲ 3.2% | 941.77M▲ 19.6% | 1.56B▲ 65.7% | 1.53B▲ 0% |
Asset Turnover | 0.21x | 0.20x | 0.08x | 0.12x | 0.19x | 0.26x | 0.17x | 0.18x | 0.17x | 0.20x |
Asset Growth % | 11.54% | 87.89% | 18.57% | -8.87% | -4.75% | -41.22% | 3.22% | 19.63% | 65.71% | 199.07% |
Total Current Liabilities | 238.87M | 82.25M | 17M | 100.11M | 41.66M | 98.81M | 16.78M | 37.11M | 37.45M | 40.67M |
Accounts Payable | 2.26M | 4.18M | 2.42M | 3.78M | 8.4M | 5.31M | 2.43M | 5.23M | 3.24M | 37.11M |
Days Payables Outstanding | 153.66 | 240.93 | 77.84 | 45.4 | 49.33 | 36.67 | 25.27 | 172.48 | 179.41 | 1.84K |
Short-Term Debt | 224.53M | 26.43M | 0 | 0 | 0 | 76.69M | 0 | 0 | 1.09M | 1.09M |
Deferred Revenue (Current) | 173K | 3.29M | 2.14M | 29.43M | 654K | 976K | 1.84M | 1.9M | 0 | 867K |
Other Current Liabilities | 1.41M | 44.3M | 7.62M | 49.38M | 22.57M | 6.26M | 4.94M | -3.2M | 25.49M | 577K |
Current Ratio | 0.99x | 10.58x | 66.09x | 5.00x | 11.15x | 2.67x | 14.15x | 8.93x | 22.23x | 21.28x |
Quick Ratio | 0.97x | 10.50x | 65.66x | 4.74x | 10.50x | 2.53x | 12.72x | 8.55x | 21.98x | 20.95x |
Cash Conversion Cycle | 210.01 | 250.47 | 283.53 | 404.22 | 249.57 | 120.35 | 333.61 | 385.42 | 409.36 | -634.36 |
Total Non-Current Liabilities | 13.51M | 617.64M | 710.68M | 552.65M | 434.77M | 66.37M | 69.52M | 74.22M | 505.98M | 494.12M |
Long-Term Debt | 18.86M | 609.86M | 638.96M | 442.29M | 320.72M | 0 | 0 | 0 | 446.19M | 446.9M |
Capital Lease Obligations | 0 | 0 | 9.97M | 5.64M | 2.26M | 10.34M | 5.75M | 5.82M | 4.2M | 17.24M |
Deferred Tax Liabilities | -22.38M | 51.97M | 32.94M | 64.6M | 30.86M | 30.61M | 31.62M | 32.52M | 52.61M | 130.14M |
Other Non-Current Liabilities | -8.88M | 7.78M | 28.82M | 40.12M | 80.94M | 25.38M | 17M | 35.88M | 2.97M | 20.61M |
Total Liabilities | 252.37M | 699.89M | 727.68M | 652.76M | 476.43M | 165.18M | 86.3M | 111.33M | 543.42M | 534.78M |
Total Debt | 224.53M | 636.3M | 650.18M | 456.41M | 324.39M | 87.75M | 6.17M | 7.11M | 451.49M | 451.98M |
Net Debt | 22.87M | -82.08M | 578.64M | 408.8M | 304.86M | 42.74M | -16.79M | -65.2M | 276.56M | 336.9M |
Debt / Equity | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x | 0.44x | 0.45x |
Debt / EBITDA | 2.79x | 3.53x | 0.76x | 6.97x | 2.10x | 1.89x | 0.13x | 0.56x | 5.58x | 3.56x |
Net Debt / EBITDA | 0.28x | -0.45x | 0.68x | 6.24x | 1.97x | 0.92x | -0.35x | -5.16x | 3.42x | 2.65x |
Interest Coverage | 6.02x | 4.59x | 23.29x | 1.05x | 4.68x | 21.02x | 98.04x | 1.83x | - | 197.45x |
Total Equity | 418.65M▲ 0% | 560.91M▲ 34.0% | 767.23M▲ 36.8% | 709.52M▼ 7.5% | 821.16M▲ 15.7% | 597.49M▼ 27.2% | 700.91M▲ 17.3% | 830.44M▲ 18.5% | 1.02B▲ 22.5% | 997.32M▲ 0% |
Equity Growth % | 12.89% | 33.98% | 36.78% | -7.52% | 15.73% | -27.24% | 17.31% | 18.48% | 22.49% | 67.69% |
Book Value per Share | 17.83 | 23.31 | 38.83 | 43.84 | 47.61 | 35.42 | 39.47 | 45.40 | 50.12 | 50.16 |
Total Shareholders' Equity | 418.65M | 560.91M | 767.23M | 709.52M | 821.16M | 597.49M | 700.91M | 830.44M | 1.02B | 997.32M |
Common Stock | 21K | 21K | 17K | 16K | 17K | 17K | 18K | 20K | 20K | 20K |
Retained Earnings | -400.92M | -229.2M | 400.11M | 391.95M | 449.09M | 450.86M | 503.02M | 498.98M | 608.09M | 594.74M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 2.49M | -1.02M | -216K | -801K | -917K | -984K | -817K | -5.94M | 8.46M | 5.39M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LGND Cash Flow Statement
Ligand Pharmaceuticals Incorporated (LGND) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 93.57M | 194.06M | -29.34M | 54.59M | 78.8M | 137.85M | 49.58M | 97.05M | 49.36M | 123.42M |
Operating CF Margin % | 66.31% | 77.18% | -24.39% | 33.37% | 32.62% | 70.24% | 37.75% | 58.07% | 18.41% | - |
Operating CF Growth % | 48.52% | 107.4% | -115.12% | 286.07% | 44.36% | 74.94% | -64.04% | 95.75% | -49.14% | 306.33% |
Net Income | 12.56M | 143.32M | 629.3M | -2.98M | 57.14M | -33.36M | 52.15M | -4.03M | 124.45M | 153.56M |
Depreciation & Amortization | 11.71M | 14.72M | 43.73M | 27.97M | 50.95M | 51.37M | 36.52M | 35.24M | 35.72M | 33.63M |
Stock-Based Compensation | 24.91M | 20.85M | 24.52M | 30.73M | 38.78M | 60.28M | 25.74M | 41.09M | 0 | 39.61M |
Deferred Taxes | 44.52M | 29.74M | 74.83M | -19.05M | -8.62M | 20.72M | 11.7M | -15.8M | 22.68M | -325K |
Other Non-Cash Items | 11.3M | 24.29M | -797.5M | 28M | -7.29M | -26.84M | -42.13M | 21.2M | -120.83M | -101.44M |
Working Capital Changes | -11.44M | -38.85M | -4.21M | -10.06M | -52.16M | 65.68M | -34.4M | 19.36M | -12.66M | -1.61M |
Change in Receivables | -8.36M | -29.54M | 25.46M | -26.06M | -28.62M | 55.32M | -2.6M | -6.46M | -21.74M | -14.75M |
Change in Inventory | -843K | -2.56M | -2.06M | -17.8M | -427K | 12.06M | -10.87M | 9.62M | 4.99M | 1.35M |
Change in Payables | -1.71M | -4.54M | -18.05M | -1.25M | -1.17M | -3.34M | -4.7M | 0 | 5.88M | 10.74M |
Cash from Investing | -84.18M | -423.27M | 466.92M | 231.65M | 30.52M | 163.62M | -11.68M | -143.66M | -377.32M | -476.56M |
Capital Expenditures | -7.15M | -11.89M | -2.55M | -4.46M | -8.76M | -17.92M | -3.52M | -1.82M | -11.31M | -466K |
CapEx % of Revenue | 5.07% | 4.73% | 2.12% | 2.73% | 3.63% | 9.13% | 2.68% | 1.09% | 4.22% | 0.17% |
Acquisitions | -26.65M | -5.86M | -12.84M | -383.32M | 494K | -750K | -25.65M | -172.19M | -8.09M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 7.25M | 3.91M | 808.13M | 3.26M | -1.22M | -868K | -49.91M | -12.89M | -4.34M | -13.74M |
Cash from Financing | -7.52M | 328.58M | -485.17M | -310.55M | -137.76M | -275.99M | -59.95M | 97.14M | 428.22M | 418.84M |
Debt Issued (Net) | 0 | 532.33M | -27.32M | -231.76M | -146.01M | -261M | -76.9M | -25K | 338.11M | 338.11M |
Equity Issued (Net) | -1.97M | -126.63M | -457.47M | -78M | 15.32M | -8.24M | 0 | 37.14M | 99.89M | 103.32M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -1.97M | -122.87M | -453.05M | -78M | -18.45M | -8.24M | 0 | 0 | -15M | -15M |
Other Financing | -5.56M | -77.11M | -383K | -789K | -7.07M | -6.75M | 16.95M | 60.03M | -9.77M | -22.59M |
Net Change in Cash | 1.87M▲ 0% | 99.16M▲ 5208.4% | -47.51M▼ 147.9% | -24.31M▲ 48.8% | -28.44M▼ 17.0% | 25.48M▲ 189.6% | -22.05M▼ 186.5% | 49.35M▲ 323.8% | 102.62M▲ 107.9% | 67.11M▲ 0% |
Free Cash Flow | 86.41M▲ 0% | 182.17M▲ 110.8% | -31.89M▼ 117.5% | 50.13M▲ 257.2% | 70.04M▲ 39.7% | 119.93M▲ 71.2% | -4.27M▼ 103.6% | 77.41M▲ 1912.0% | 48.91M▼ 36.8% | 122.96M▲ 0% |
FCF Margin % | 61.24% | 72.45% | -26.51% | 30.65% | 29% | 61.11% | -3.25% | 46.31% | 18.24% | 44.8% |
FCF Growth % | 149.18% | 110.81% | -117.5% | 257.2% | 39.72% | 71.23% | -103.56% | 1911.96% | -36.82% | 246.42% |
FCF per Share | 3.68 | 7.57 | -1.61 | 3.10 | 4.06 | 7.11 | -0.24 | 4.23 | 2.41 | 6.18 |
FCF Conversion (FCF/Net Income) | 7.45x | 1.35x | -0.05x | -18.29x | 1.38x | -4.13x | 0.95x | -24.07x | 0.40x | 0.80x |
Interest Paid | 1.84M | 1.51M | 5.83M | 4.46M | 3.03M | 1.43M | 288K | 263K | 0 | 98K |
Taxes Paid | 157K | 341K | 103.82M | 2.13M | 3.72M | 11.64M | 8.77M | 19.21M | 0 | 621K |
LGND Key Ratios
Ligand Pharmaceuticals Incorporated (LGND) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 3.18% | 29.26% | 94.76% | -0.4% | 7.47% | -4.7% | 8.03% | -0.53% | 13.47% | 16.19% |
Return on Invested Capital (ROIC) | 11.55% | 26.68% | 66.35% | 2.28% | 6.94% | 0.26% | 1.35% | -2.34% | 3.44% | 6.49% |
Gross Margin | 96.2% | 97.48% | 90.57% | 81.4% | 74.26% | 73.08% | 73.31% | 93.37% | 97.54% | 98.61% |
Net Margin | 8.9% | 57% | 523.19% | -1.82% | 23.66% | -17% | 39.72% | -2.41% | 46.42% | 55.95% |
Debt / Equity | 0.54x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x | 0.44x | 0.45x |
Interest Coverage | 6.02x | 4.59x | 23.29x | 1.05x | 4.68x | 21.02x | 98.04x | 1.83x | - | 197.45x |
FCF Conversion | 7.45x | 1.35x | -0.05x | -18.29x | 1.38x | -4.13x | 0.95x | -24.07x | 0.40x | 0.80x |
Revenue Growth | 29.48% | 78.21% | -52.17% | 35.98% | 47.68% | -18.75% | -33.09% | 27.28% | 60.4% | 51.24% |
Related:LGND Dividend History·LGND Revenue History·LGND Price History·LGND P/E History·LGND Financial Ratios·LGND Institutional Holders
LGND SEC Filings & Documents
Ligand Pharmaceuticals Incorporated (LGND) SEC filings — annual & quarterly reports (10-K, 10-Q)
LGND Frequently Asked Questions
Ligand Pharmaceuticals Incorporated (LGND) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ligand Pharmaceuticals Incorporated (LGND) reported $274.5M in revenue for fiscal year 2025. This represents a 646% increase from $36.8M in 1996.
Ligand Pharmaceuticals Incorporated (LGND) grew revenue by 60.4% over the past year. This is strong growth.
Yes, Ligand Pharmaceuticals Incorporated (LGND) is profitable, generating $153.6M in net income for fiscal year 2025 (46.4% net margin).
Dividend & Returns
Ligand Pharmaceuticals Incorporated (LGND) has a return on equity (ROE) of 13.5%. This is reasonable for most industries.
Ligand Pharmaceuticals Incorporated (LGND) generated $123.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.